Platinum Industries Management Guidance Tracker

Management expects standalone revenue growth exceeding 40% in FY27, driven by Palar ramp-up and Egypt commissioning.

New pharma subsidiary (Rivardu Life Sciences) expected to generate revenue in FY27, though no specific figures provided.

Management targets >40% revenue growth in FY27, with 10% from Egypt and rest from India.

Company targets a 35% compound annual growth rate over the next three years, excluding pharma business.

Long-term revenue CAGR target of 35% over FY26-29, supported by Egypt ramp-up and new products.

Egypt plant construction to complete by end of May 2026, pre-commissioning in June, commercial production by September 2026.

Egypt facility to start commercial production in Q3 FY27, contributing ~10% of FY27 revenue.

Management expects to maintain EBITDA margin in 13-15% range in FY27.